Journal
CIRCULATION RESEARCH
Volume 97, Issue 11, Pages 1124-1131Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/01.RES.0000194323.77203.fe
Keywords
C-reactive protein; endothelial NO synthase; Fc gamma receptor; PP2A
Funding
- NHLBI NIH HHS [HL75473, HL06296] Funding Source: Medline
- NIA NIH HHS [AG02467] Funding Source: Medline
Ask authors/readers for more resources
C-reactive protein (CRP) is an acute-phase reactant that is positively correlated with cardiovascular disease risk and endothelial dysfunction. Whether CRP has direct actions on endothelium and the mechanisms underlying such actions are unknown. Here we show in cultured endothelium that CRP prevents endothelial NO synthase (eNOS) activation by diverse agonists, resulting in the promotion of monocyte adhesion. CRP antagonism of eNOS occurs nongenomically and is attributable to blunted eNOS phosphorylation at Ser1179. Okadaic acid or knockdown of PP2A by short- interference RNA reverses CRP antagonism of eNOS, indicating a key role for the phosphatase. Aggregated IgG, the known ligand for Fc gamma receptors, causes parallel okadaic acid-sensitive loss of eNOS function, Fc gamma RIIB expression is demonstrable in endothelium, and heterologous expression studies reveal that CRP antagonism of eNOS requires Fc gamma RIIB. In Fc gamma RIIB (+/+) mice, CRP blunts acetylcholine-induced increases in carotid artery vascular conductance; in contrast, CRP enhances acetylcholine responses in Fc gamma RIIB-/(-) mice. Thus Fc gamma RIIB mediates CRP inhibition of eNOS via PP2A, providing a mechanistic link between CRP and endothelial dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available